TACL / Amgen Carfilzomib study

20140106 (formerly CFZ008); Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia
Carfilzomib (also known as Kyprolis®) is approved to be used in certain adult patients with relapsed or refractory multiple myeloma (myeloma that returns after a successful course of treatment or myeloma that does not respond to treatment). Multiple myeloma is a type of blood cancer. Carfilzomib is not approved to treat ALL. It has not been given in combination with the other drugs used in this study. This study is being done to find out if carfilzomib can be safely given before and during treatment with standard chemotherapy drugs.
CHLA IRB Number
CCI-CG-06-00012
Study Type
Drug Treatment
Eligibility
Age 1 to 21 with leukemia (ALL) that has returned after an initial response to treatment or failed to respond to initial treatment
Clinical Trials Government Identifier
NCT02303821
Enrollment Status
Open
Does this study also recruit healthy volunteers?
No
Coordinator Contact
Ellynore Florendo
Contact Email
TACL@chla.usc.edu
Coordinator Contact
Meg Fender